Office: South San Francisco, CA
Kurt C. Wheeler
Kurt Wheeler has been Managing Director of Clarus since the firm’s inception in 2005. Prior to Clarus, Mr. Wheeler was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 30 years of direct investment and industry experience within the healthcare sector.
Mr. Wheeler was founder and CEO of InControl (NASDAQ:INCL), a medical device company sold to Guidant. Prior to founding InControl he was a Principal with the Mayfield Fund focused on healthcare investing. Mr. Wheeler began his career with Elli Lilly & Co.
Mr. Wheeler holds a BA from Brigham Young University, and a MBA from Northwestern University’s Kellogg School.
Current Board Seats
Previous Board Seats
CHF Solutions (acquired by Gambro)
Hemosense (AMEX:HEM) (acquired by Inverness Medical)
InControl (NASDAQ:INCL)(aquired by Guidant)
Intrathrerapeutics (acquired by Sulzer Medica)
Eyetech Pharmaceuticals (NASDAQ:EYET)
SenoRx (NASDAQ:SENO) (acquired by CR Bard)
Neuromed Pharmaceuticals (NASDAQ:ZLCS)
Somaxon Pharmaceuticals (NASDAQ:SOMX)